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Chronic Infantile Neurological Cutaneous Articular (CINCA) syndrome, also called Neonatal Onset Multisystem
Inflammatory Disease (NOMID) is a chronic disease with early onset affecting mainly the central nervous system, bones
and joints and may lead to permanent damage. We report two preterm infants with severe CINCA syndrome treated
by anti-interleukin-1 in the neonatal period, although, so far, no experience with this treatment in infants younger
than three months of age has been reported. A review of the literature was performed with focus on treatment and
neonatal features of CINCA syndrome.
Case report: Two cases suspected to have CINCA syndrome were put on treatment with anakinra in the early neonatal
period due to severe clinical presentation. We observed a rapid and persistent decline of clinical signs and systemic
inflammation and good drug tolerance. Diagnosis was confirmed in both cases by mutations in the NLRP3/CIAS1-gene
coding for cryopyrin. As particular neonatal clinical signs polyhydramnios and endocardial overgrowth are to be
mentioned.
Conclusion: We strongly suggest that specific treatment targeting interleukin-1 activity should be started early. Being
well tolerated, it can be introduced already in neonates presenting clinical signs of severe CINCA syndrome in order to
rapidly control inflammation and to prevent life-long disability.
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Chronic Infantile Neurological Cutaneous Articular
syndrome (CINCA) (OMIM 607’115), also called Neonatal
Onset Multisystem Inflammatory Disease (NOMID), is the
most severe form of the Cryopyrin-Associated Periodic
Syndromes (CAPS), a continuum of diseases with muta-
tions of the CIAS1-gene also called NLRP3, coding for
cryopyrin. It is clinically characterized by the triad of
key symptoms (rash, joint involvement and neurological
manifestations) in varying severity due to excessive pro-
duction of IL-1β [1,2].
Although the first manifestations of CINCA syndrome
may be present at birth, neonatal diagnosis is rare and no
experience with specific treatment targeting interleukin-1
activity before three months of age is described in the
literature [3-9].* Correspondence: Matthias.Roth@chuv.ch
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unless otherwise stated.Here we present two preterm cases of severe CINCA
syndrome with early diagnosis and neonatal start of
treatment with anakinra, in order to avoid long-term
sequelae. We also present some additional potential
congenital manifestations of the disease.
Case presentation
Case report 1
This preterm boy was born at 33 6/7 weeks of gestation
after a pregnancy complicated by severe polyhydramnios
appearing at 30 weeks of gestation and needing several
therapeutic amniocenteses. Extensive search for the
aetiology of polyhydramnios was without result. During
an amniotic puncture, the patient manifested severe
bradycardia, leading to emergency caesarean section.
The patient was apnoeic, pale and showed significant
hepato-splenomegaly. Resuscitation procedures included
positive pressure ventilation, crystalloid and blood admin-
istration. The placenta was of augmented weight showing
histological signs of umbilical cord infection, but no
placental abruption was apparent. Initial laboratory results
showed hemoglobin of 71 g/L, leucocytes 52.2×109/L,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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aspartate aminotransferase 639 U/L, alanine aminotransfer-
ase (ALT) 86 U/L, total bilirubin 85 (direct 69) μmol/L.
Cerebrospinal fluid (CSF) analysis showed 27×106/L cells
(62% neutrophils) and protein 1.19 g/L. Amoxicilline
and gentamicine were initiated. A few hours after birth,
the patient developed a fluctuating urticarial rash and
was febrile during the first few days. Echocardiography
showed a lesion similar to infectious vegetation at the
pulmonary valve (Figure 1). An extended microbiological
evaluation was undertaken: PCR was negative in blood for
Parvovirus B19, EBV, in urine for CMV, and in CSF for
CMV, Parvovirus and toxoplasmosis. Hepatitis B serology
was negative. Serial blood cultures were sterile.
Cerebral MRI was normal except for enlarged pericer-
ebral spaces. Auditory evoked potentials (AEPs) showed
unilateral neurosensory deafness (left: 80 dB, right: 40 dB).
Ophthalmologic evaluation was normal. Cholestasis which
we attributed to parenteral nutrition and the inflammatory
process worsened reaching a maximum total bilirubin of
174 μmol/L (direct 147 μmol/L), and ALT 467 U/L. On
day 10, the patient developed arthritis of small finger
joints, wrists and knees. Antinuclear antibodies and
rheumatoid factor were normal; C3 complement factor
and serum amyloid A (41.8 mg/L) were elevated. CINCA
syndrome was diagnosed based on the symptoms and the
absence of infection. After discussion with the parents and
their consent, treatment with anakinra (2 mg/kg/day, sc)
was initiated at day 17. Already after three injections
the rash disappeared, CRP reached normal values, and
the arthritis improved. However, as the existing litera-
ture about anakinra had mentioned that higher doses
were needed in young infants (>3 months) with up to
10 mg/kg/d, we increased the dose stepwise up toFigure 1 Cardiac vegetation in neonatal CINCA syndrome. Echocardiog
The pulmonary valve is closed and a thin posterior leaflet is clearly visible (
lesion (white arrow head) is attached to its ventricular side. (LV: left ventricl7 mg/kg/d in order to get the patient free of any sign of
arthritis [5]. Thrombocytopenia resolved but anaemia
persisted for 8 weeks. The endocardial lesion of the
pulmonary valve was still present at 8 weeks, however,
disappeared without specific treatment by 6 months.
Cholestasis slowly resolved in parallel to the decreasing
inflammatory reaction and due to treatment with urso-
deoxycholic acid and semi-elementary diet. After three
weeks of treatment with anakinra, an acute urinary
tract infection (UTI) due to Escherichia coli was treated
by antibiotics. Anakinra dose was transitorily decreased,
whereas today rather an increase of the dose is suggested
[4]. After 6 months of treatment, anakinra was reduced to
3 mg/kg/day and the disease remained inactive. At
12 months, neurological evaluation was normal and AEPs
showed a moderate neurosensory deafness on both sides
(left: 65 dB; right: 50 dB). Ophthalmologic evaluation
remained normal at 1 and 2 months. Genetic testing
exhibited a heterozygote mutation E567K (p.GLU567Lys)
of the NLRP3 gene [10].
Case report 2
Born vaginally at 34 4/7 weeks of gestation (birth weight
2650 g), this girl was transferred after normal adaptation
to the tertiary centre because of a cutaneous rash starting
7 hours after birth for suspicion of sepsis. She was afebrile,
stable cardio-respiratory-wise with a normal neurological
status. Urticarial rash was covering her whole body
(Figure 2). Blood workup showed normal formula and
blood gas values, but increased inflammation parameters
(CRP 101 mg/L, Interleukin-6 528 ng/L). CRP raised
(137 mg/L) despite initiation of amoxicillin, gentamicine
and fluconazole intravenously. Because of sterile blood
cultures and absence of clinical signs of infection, theraphic long axis parasternal view of the right ventricular outflow tract.
white arrow). The anterior leaflet is thicker and a hyperechogenic
e; PA: pulmonary artery trunk; RV: right ventricle).
Figure 2 Cutaneous rash in neonatal CINCA syndrome.
Figure 3 Arthritis in neonatal CINCA syndrome.
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36×106/L leucocytes and cultures were sterile. Cerebral and
abdominal ultrasonographies were normal. On day six she
developed arthritis in small joints of hands (Figure 3) and
feet. Arthritis, together with the rash and the persisting ele-
vated inflammation markers led to the diagnosis of CINCA
syndrome. The patient was discharged home with decreas-
ing urticarial rash but persistent arthritis. On day 32, the
girl developed fever (38.2°C), with CRP rising to 222 mg/L.
This severe evolution prompted parents to accept treat-
ment with anakinra at 39 weeks postmenstrual age. The
goals of this treatment were to get the patient free of
symptoms and to suppress the inflammatory reaction
and reaching normal CRP values. To achieve these
goals the dose had to be increased temporarily to
20 mg/kg/d which was well tolerated. At 2 months,
therapy was switched to canakinumab, 8 mg/kg sc,
every 5–6 weeks without symptoms or increase of inflam-
matory parameters [11]. At 20 months, neurodevelopment,
brain MRI, AEPs and ophthalmologic examination were
normal. In the NLRP3-gene a heterozygous mutation for
F566L (p.Phe566Leu) was identified [10].
Discussion
CINCA syndrome is a chronic disease with onset in the
neonatal period. A severe course affecting mainly thecentral nervous system, bones and joints, may lead to
permanent damage in these organs. Since the early 2000s,
a specific treatment, able to control systemic inflammation
is available [4]. Therefore, early diagnosis is warranted to
start treatment before the occurrence of sequelae induced
by the inflammatory process.
Both patients were diagnosed in the neonatal period
based on the classical clinical features, and after exclusion
of a neonatal infection. Often associated to CINCA syn-
drome are prematurity, intrauterine growth retardation and
oligohydramnios. In addition to the typical symptoms,
case 1 presented with severe anaemia and thrombocyto-
penia, cholestasis, endocardial lesion and polyhydramnios.
Anaemia and associated hepato-splenomegaly are well
described in CINCA patients [12]. Thrombocytopenia,
so far not associated, might be related to the severe
anaemia with increased erythropoiesis due to diversion
of hematopoietic stem cells away from platelet formation
[12,13]. Macrophage activation syndrome was excluded
by normal levels of ferritin and triglycerides. Whereas
in recent literature oligohydramnios in CINCA patients
has been linked to placenta insufficiency, polyhydramnios
was suggested to be a sign of severity of prenatal involve-
ment [14]. The cardiac lesion in the absence of infection
is a unique finding and might represent a pathological
overgrowth of cells due to the deregulation of the
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scribed in knees of NOMID patients [15]. To exclude a
process corresponding to Libman-Sacks endocarditis de-
scribed in patients with systemic lupus, we searched for
antinuclear antibodies which were negative [16].
CAPS are associated with gain-of-function mutations
of the NLRP3/CIAS1-gene, coding for cryopyrin [1,17].
Until now, there are more than 170 mutations described
[18]. The two mutations found in the here presented
patients have been found in other patients: the E567K
mutation in a 26 year old woman with Muckle Wells
syndrome, another form of CAPS, and the F556L muta-
tion in a 5 year old boy with CINCA syndrome leading
to motor developmental delay, mild conductive hearing
loss and focal cortical dysplasia with epileptic seizures
[19-21]. Due to a wide range of phenotypic heterogeneity,
phenotype and mutations do not match well [7,10,22].
Moreover, only in half of typical CINCA patients a muta-
tion in the NLRP3 gene could be found by conventional
sequencing. Further subcloning and sequencing of NLRP3
may detect a somatic NLRP3 mosaicism in primary
genetic-negative CINCA patients [10]. Therefore, the
clinician should rely on the clinical features to assess
the diagnosis, in particular in young infants.
Due to the central role of excessive IL-1β activity, the
contemporary treatment consists in competitively inhibit-
ing IL-1 receptor (anakinra), in diminishing IL-1 activity
by IL-1 binding protein (rilonacept) or human anti-IL-1β
monoclonal antibody (canakinumab) [1]. Treatment with
anakinra was shown to be safe but has not yet been used
at neonatal age [3-5,23]. Anakinra has recently been
approved for use in children aged ≥8 months. Because of
its short half-life of a few hours, anakinra is the treatment
of choice in patients in which the drug tolerance has not
been clearly established, e.g. newborn infants and paediatric
patients. In regards to the potentially severe sequelae of the
disease, the safety of the anti-IL-1 treatment, and the limita-
tions of the genetic results due to phenotypic heterogeneity
and frequent mosaicism, genetic testing is not required for
starting to use anakinra [4,5,7]. According to the literature,
patients diagnosed in younger age needed higher doses
of anakinra and required more frequent treatment adjust-
ments than adults [4,5]. Except for an UTI in Case 1,
neither patient showed any of the known side effects or
complications of the treatment, like injection site reaction,
infections particularly by encapsulated-germs, influenza-
like symptoms, nausea, diarrhoea, or neutropenia.
The long-term outcome of patients with CINCA syn-
drome depends on the severity and duration of the
inflammatory process. Hearing loss reversibility seems to
be correlated with early treatment [1,2,4]. It is suggested
that complications may be prevented if adequate and
efficient treatment is started before the appearance of
irreversible lesions [23].Conclusion
The clinical triad of cutaneous rash, arthritis and meningi-
tis-like symptoms, associated with severe inflammation
without infection should point, already in newborn
infants, towards the diagnosis of CINCA syndrome. These
two cases suggest that, in severe situations, treatment
can be initiated safely in neonates in order to prevent
irreversible organ damage and life-long disability. Results
of genetic testing are not required before initiation of
treatment, as in many cases conventional sequencing for
NLRP3 mutations is negative.
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